Italia markets closed

FTSE MIB
34.249,77
+310,02(+0,91%)
Dow Jones
38.239,66
+153,86(+0,40%)
Nasdaq
15.927,90
+316,14(+2,03%)
Nikkei 225
37.934,76
+306,28(+0,81%)
Petrolio
83,66
+0,09(+0,11%)
Bitcoin EUR
59.640,77
+837,67(+1,42%)

Organon & Co. (OGN)

NYSE - NYSE Prezzo differito. Valuta in USD.

Aggiungi a watchlist

18,55

+0,13

(+0,71%)

Alla chiusura: 04:00PM EDT

18,40

-0,15

(-0,81%)

Dopo ore:

07:49PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	4,742B
Beta (5 anni mensile)	0,79
Rapporto PE (ttm)	4,65
EPS (ttm)	3,99
Prossima data utili	02 mag 2024
Rendimento e dividendo (futuro)	1,12 (6,04%)
Data ex dividendo	23 feb 2024
Stima target 1A	21,50

Tutte

GlobeNewswire
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab). The Phase 4, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study (NCT05510063) for SB5 was conducted across 33 sites in four countries (Bulgaria, Czechia, Lithuania, Poland) from August 2022 to May 2023
GlobeNewswire
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreementSAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023. “We